| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1998;98:2141-2147.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
Influence of the Novel Inotropic Agent Levosimendan on Isometric Tension and Calcium Cycling in Failing Human Myocardium
From the Zentrum Innere Medizin, Abteilung für Kardiologie und Pneumologie, Universität Göttingen (G.H., B.P., L.M.), and the Medizinische Klinik III, Abteilung für Kardiologie und Angiologie, Universität Freiburg (M.C., B.K., H.J.), Germany.
Correspondence to Gerd Hasenfuss, MD, Universität Göttingen, Zentrum Innere Medizin, Abteilung Kardiologie und Pneumologie, Robert-Koch-Straße 40, 37075 Göttingen, Germany. E-mail hasenfus{at}med.uni-goettingen.de
Background—Levosimendan was shown to increase calcium sensitivity by a novel mechanism and to inhibit phosphodiesterase III activity in animal myocardium.
Methods and Results—We investigated the influence of levosimendan on isometric contractions and calcium transients (aequorin method) in muscle strips from human hearts with end-stage failing dilated or ischemic cardiomyopathy (n=27). Data were compared with the effects of the phosphodiesterase inhibitor milrinone (n=9). The average maximum increase in twitch tension was 47±14% (range, 6% to 150%) at a levosimendan concentration of 0.8±0.3 µmol/L (P<0.01). This was associated with significant increases in maximum rates of tension rise and fall and decreases in times to peak tension, to 50% relaxation, and to 95% relaxation. In aequorin-loaded muscles, levosimendan 10-6 mol/L increased average tension by 50% (P<0.02), associated with a nonsignificant increase in aequorin light (16%). With milrinone 10-5 mol/L, average tension increased by 58% and aequorin light by 49% (P<0.05). In those muscle strips with pronounced inotropic effects (>50% increase in tension), there was a comparable and pronounced increase in aequorin light with both agents. However, in muscle strips with weak inotropic responses (<50% increase in tension), the increase in light was significantly higher with milrinone than with levosimendan.
Conclusions—Levosimendan has inotropic and lusitropic actions in failing human myocardium. Comparison with the phosphodiesterase inhibitor milrinone indicates that in case of pronounced inotropic stimulation, the modes of action of the two agents may be similar (phosphodiesterase inhibition), whereas small inotropic effects of levosimendan may result predominantly from calcium sensitization.
Key Words: levosimendan • calcium • myocardium • heart failure
This article has been cited by other articles:
 |
|
 |
|
  T. Varpula, J. Rapola, M. Sallisalmi, and J. Kurola Treatment of Serious Calcium Channel Blocker Overdose With Levosimendan, a Calcium Sensitizer Anesth. Analg., March 1, 2009; 108(3): 790 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Overgaard and V. Dzavik Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease Circulation, September 2, 2008; 118(10): 1047 - 1056. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masutani, H.-J. Cheng, M. Hyttila-Hopponen, J. Levijoki, A. Heikkila, A. Vuorela, W. C. Little, and C.-P. Cheng Orally Available Levosimendan Dose-Related Positive Inotropic and Lusitropic Effect in Conscious Chronically Instrumented Normal and Heart Failure Dogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 236 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jorgensen, O. Bech-Hanssen, E. Houltz, and S.-E. Ricksten Effects of Levosimendan on Left Ventricular Relaxation and Early Filling at Maintained Preload and Afterload Conditions After Aortic Valve Replacement for Aortic Stenosis Circulation, February 26, 2008; 117(8): 1075 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 629 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Trikas, C. Antoniades, G. Latsios, K. Vasiliadou, I. Karamitros, D. Tousoulis, C. Tentolouris, and C. Stefanadis Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure Eur J Heart Fail, December 1, 2006; 8(8): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T Parissis, S Adamopoulos, D Farmakis, G Filippatos, I Paraskevaidis, F Panou, E Iliodromitis, and D Th Kremastinos Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart, December 1, 2006; 92(12): 1768 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tokuda, P. W. Grant, H. D. Wolfenden, C. Manganas, W. J. Lyon, and J. S.K. Murala Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery Interactive CardioVascular and Thoracic Surgery, June 1, 2006; 5(3): 322 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass and R. J. Solaro Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart Circulation, January 17, 2006; 113(2): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
D. Moertl, R. Berger, M. Huelsmann, A. Bojic, and R. Pacher Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure Eur J Heart Fail, December 1, 2005; 7(7): 1156 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dernellis and M. Panaretou Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: A Combined Hemodynamic and Doppler Echocardiographic Study Chest, October 1, 2005; 128(4): 2633 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF]
|
|
|
|
|
|
D. von Lewinski, S. Bruns, S. Walther, H. Kogler, and B. Pieske Insulin Causes [Ca2+]i-Dependent and [Ca2+]i-Independent Positive Inotropic Effects in Failing Human Myocardium Circulation, May 24, 2005; 111(20): 2588 - 2595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tachibana, H.-J. Cheng, T. Ukai, A. Igawa, Z.-S. Zhang, W. C. Little, and C.-P. Cheng Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H914 - H922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Hamlin, P. S. Villars, J. T. Kanusky, and A. D. Shaw Role of Diastole in Left Ventricular Function, II: Diagnosis and Treatment Am. J. Crit. Care., November 1, 2004; 13(6): 453 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward?: Part II: Chronic Inotropic Therapy Circulation, July 29, 2003; 108(4): 492 - 497. [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Vroom Epidemiology and Pharmacotherapy of Acute Heart Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 3 - 12. [PDF]
|
|
|
|
|
|
J.G.F. Cleland, A. Takala, M. Apajasalo, N. Zethraeus, and G. Kobelt Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial Eur J Heart Fail, January 1, 2003; 5(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brixius, S. Reicke, and R. H. G. Schwinger Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H131 - H137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E du Toit, D Hofmann, J McCarthy, and C Pineda Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model Heart, July 1, 2001; 86(1): 81 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Nieminen, J. Akkila, G. Hasenfuss, F. X. Kleber, L. A. Lehtonen, V. Mitrovic, O. Nyquist, W. J. Remme, and on behalf of the Study Group Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1903 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Slawsky, W. S. Colucci, S. S. Gottlieb, B. H. Greenberg, E. Haeusslein, J. Hare, S. Hutchins, C. V. Leier, T. H. LeJemtel, E. Loh, et al. Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure Circulation, October 31, 2000; 102(18): 2222 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sorsa, S. Heikkinen, M. B. Abbott, E. Abusamhadneh, T. Laakso, C. Tilgmann, R. Serimaa, A. Annila, P. R. Rosevear, T. Drakenberg, et al. Binding of Levosimendan, a Calcium Sensitizer, to Cardiac Troponin C J. Biol. Chem., March 16, 2001; 276(12): 9337 - 9343. [Abstract] [Full Text] [PDF]
|
|